CellaVision AB (publ) (STO:CEVI)

Market Cap	3.75B
Revenue (ttm)	748.45M
Net Income (ttm)	151.41M
Shares Out	23.85M
EPS (ttm)	6.35
PE Ratio	24.76
Forward PE	21.47
Dividend	2.50 (1.59%)
Ex-Dividend Date	May 7, 2025

Volume	6,481
Average Volume	15,144
Open	156.80
Previous Close	157.20
Day's Range	156.00 - 157.60
52-Week Range	147.80 - 232.50
Beta	1.36
RSI	49.50
Earnings Date	Feb 5, 2026

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers and instruments; and hardware products, including in vitro diagnostics IVD for laboratories; smear makers, stainers, stains, and staining protocols; DIFF-Line, a hematology lab that handles a smaller amount daily blood samples, as well as consists of three instruments, such as CellaVision DC-1, RAL SmearBox, and RAL StainBox...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 219
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.